Meeting
2014 Genitourinary Cancers Symposium
ARMOR2: Galeterone in progressive CRPC patients who have failed oral therapy.
Authors
Mary-Ellen Taplin
Dana-Farber Cancer Institute, Boston, MA
Mary-Ellen Taplin , Robert B. Montgomery
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
01709734
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 71)
DOI
10.1200/jco.2014.32.4_suppl.71
Abstract #
71
Poster Bd #
E6
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Galeterone in men with CRPC: Results in four distinct patient populations from the ARMOR2 study.
First Author: Robert B. Montgomery
Poster
2016 ASCO Annual Meeting
Galeterone in treatment-naïve patients with castration-resistant prostate cancer with C-terminal androgen receptor loss: Results from ARMOR2.
First Author: Mary-Ellen Taplin
Poster
2014 Genitourinary Cancers Symposium
Prospective evaluation of low-dose ketoconazole plus hydrocortisone (HC) in chemotherapy-pretreated castration-resistant prostate cancer (CRPC) patients.
First Author: Ernest N. Lo
Poster
2012 Genitourinary Cancers Symposium
Response to abiraterone acetate in the postchemotherapy setting in patients with castration-resistant prostate cancer whose disease progresses early on docetaxel.
First Author: Deborah Mukherji